Cadrenal Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVKD research report →
Range $32 – $32
Price Chart
About the company
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation.
- CEO
- Quang X. Pham
- IPO
- 2023
- Employees
- 5
- HQ
- Ponte Vedra, FL, US
Get TickerSpark's AI analysis on CVKD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.53M
- P/E
- -0.20
- Fwd P/E
- 0.12
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.70
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -406.38%
- ROIC
- -284.81%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,461,177
- Net Income
- $-13,237,362-24.3%
- EPS
- $-6.64+23.9%
- OCF Growth
- -71.3%
- FCF Growth
- -71.1%
- 52W High
- $14.50
- 52W Low
- $0.85
- 50D MA
- $1.49
- 200D MA
- $4.57
- Beta
- 1.84
- RSI (14)
- 34
- Avg Volume
- 433.10K
No earnings-call transcripts are available for CVKD yet.
- Free Float
- 87.9%
- Shares Outstanding
- 3.57M
- Float Shares
- 3.14M
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 53.91K | ▼ 327 |
| Vanguard Capital Management LLC | 50.14K | ▲ 4.94K |
| Hrt Financial LP | 29.05K | ▲ 29.05K |
| Geode Capital Management, LLC | 19.02K | ▼ 2.60K |
| Vanguard Fiduciary Trust Co | 8.31K | 0 |
| Tower Research Capital LLC (Trc) | 1.28K | ▲ 889 |
| Ubs Group AG | 1.11K | ▲ 1.11K |
| Grove Bank & Trust | 1.00K | ▲ 1.00K |
| Morgan Stanley | 706 | ▲ 606 |
| Clearstead Advisors, LLC | 650 | ▲ 650 |
| Quest 10 Wealth Builders, Inc. | 380 | ▲ 380 |
| Advisor Group Holdings, Inc. | 300 | 0 |
Held by 22 ETFs
Biggest fund positions in CVKD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Pham Quang X | sell | 7,400 |
| Jun 25, 26 | Pham Quang X | sell | 2,127 |
| Jun 26, 26 | Pham Quang X | sell | 9,029 |
| Jun 22, 26 | Pham Quang X | sell | 9,167 |
| Jun 23, 26 | Pham Quang X | sell | 2,277 |
| Jun 16, 26 | Pham Quang X | sell | 3,613 |
| Jun 17, 26 | Pham Quang X | sell | 513 |
| Jun 11, 26 | Pham Quang X | sell | 1,462 |
| Jun 12, 26 | Pham Quang X | sell | 12,996 |
| Jun 15, 26 | Pham Quang X | sell | 3,666 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CVKD coverage
Recent articles, reports, and earnings notes.
No research on CVKD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVKD report →Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com · Sep 21
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
globenewswire.com · Sep 3
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
globenewswire.com · Aug 31
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
globenewswire.com · Aug 13
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
globenewswire.com · Aug 3
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
globenewswire.com · Jul 21
Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
globenewswire.com · Jul 13
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.